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Abstract
Breakdown of B cell tolerance is a cardinal feature of systemic lupus erythematosus (SLE).
Increased numbers of autoreactive mature naïve B cells have been described in SLE pa-
tients and autoantibodies have been shown to arise from autoreactive and non-autoreactive
precursors. How these defects, in the regulation of B cell tolerance and selection, influence
germinal center (GC) reactions that are directed towards foreign antigens has yet to be in-
vestigated. Here, we examined the characteristics of post-GC foreign antigen-specific B
cells from SLE patients and healthy controls by analyzing monoclonal antibodies generated
from plasmablasts induced specifically by influenza vaccination. We report that many of the
SLE patients had anti-influenza antibodies with higher binding affinity and neutralization ca-
pacity than those from controls. Although overall frequencies of autoreactivity in the influen-
za-specific plasmablasts were similar for SLE patients and controls, the variable gene
repertoire of influenza-specific plasmablasts from SLE patients was altered, with increased
usage of JH6 and long heavy chain CDR3 segments. We found that high affinity anti-influ-
enza antibodies generally characterize the plasmablast responses of SLE patients with low
levels of autoreactivity; however, certain exceptions were noted. The high-avidity antibody
responses in SLE patients may also be correlated with cytokines that are abnormally ex-
pressed in lupus. These findings provide insights into the effects of dysregulated immunity
on the quality of antibody responses following influenza vaccination and further our under-
standing of the underlying abnormalities of lupus.
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Introduction
During normal B cell development, most autoreactive B cells are removed by tolerance mecha-
nisms. This is evident in the drastic decrease in the numbers of self-reactive B cells in healthy
individuals from 76% of the early immature compartment to 20% of the mature naïve B cell
compartment [1]. However, in patients with systemic lupus erythematosus (SLE), primary B
cell tolerance fails and there is instead an accumulation of self-reactive mature naïve B cells
(44%), which persists even in patients who are in clinical remission [2, 3].
It was recently demonstrated in a mouse model that autoreactive B cells that recognize both
self and foreign antigens can be recruited into germinal centers (GCs), where somatic hyper-
mutation can reduce reactivity to self but maintain reactivity to the foreign antigen [4]. In the
context of SLE, it is unclear whether autoreactive B cells participate in immune responses to
foreign antigens. Autoreactive precursors do give rise to autoantibodies, which are the hallmark
phenotype of SLE [5]. However, so do non-autoreactive precursors by somatic hypermutation
and affinity maturation against self-antigens, indicating that maintenance of secondary toler-
ance in the germinal centers (GCs) of SLE patients is also defective [5–9]. Autoreactive 9G4 B
cells encoded by VH4-34, that fail to progress past the early stages of GC reactions in healthy
individuals, are significantly expanded in the post-GC IgG memory and plasma cell compart-
ments of SLE patients [10, 11]. Hence, the participation of autoreactive B cells in immune re-
sponses against foreign antigens could potentially lead to increased autoreactive responses in
SLE patients. Whether pathological autoantibodies arise in SLE patients during foreign-antigen
immune responses is an important concern in the context of infections and vaccinations. Re-
ports of plasmablast frequencies in SLE patients that wane and swell relative to disease state
suggest that there are ongoing or recurrent autoimmune responses induced by either self- or
foreign antigens [12, 13]. However, on the whole, SLE patients and healthy controls have been
reported to have similar overall frequencies of IgG memory B cells that are autoreactive [5].
With regards to vaccinations, several studies have shown that at the serological level, SLE dis-
ease activity is generally not altered after vaccination, although in certain patients temporary
increases in serum autoantibody titers may be observed [14–18]. It is not known if these in-
creases in autoantibody titers signify increased self-antigen immune responses or increased lev-
els of cross-reactivity to self-antigens in the foreign antigen-specific compartment
following vaccination.
The impact of both an autoreactive B cell repertoire and defective secondary tolerance on
the quality of immune responses to foreign antigens is not well characterized. It is unclear how
the binding characteristics of foreign antigen-specific B cells are altered in SLE patients, who
have several other immune system abnormalities. Thus far, antibody responses of SLE patients
to vaccinations have been studied only at the level of serology. Distinguishing between the
quality of individual antigen-specific B cells from the overall quantity of the polyclonal anti-
body response is challenging when relying only on serum. Furthermore, some studies report
no significant differences in the serum antibody titers between vaccinated SLE patients and
controls [19, 20] while others report that SLE patients have lower serological responses [14, 21,
22]. This may be a consequence of the heterogeneity of the patient cohorts and factors such as
lymphopenia, which influence the quantity of the response [17, 18, 23, 24]. It has been reported
that patients experiencing disease flares or having higher titers of antinuclear antibodies gener-
ally have lower responses to vaccination [17]. This could indicate that the participation of auto-
reactive B cells, naïve or memory, in GC reactions against foreign antigens may be detrimental
to the quality of the response.
Alternatively, the participation of autoreactive B cells in foreign-antigen immune responses
may be advantageous. Broadly neutralizing HIV antibodies (BnAbs) isolated from infected
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individuals are autoreactive and bind strongly to autoantigens [25–27]. It has been suggested
that SLE patients might be able to develop these BnAbs more efficiently as they are unable to
delete autoreactive B cells [28–30]. This may explain the disproportionately low occurrence of
HIV infections in SLE patients [31–33]. It has also been reported that polyreactivity increases
the avidity of polyreactive anti-HIV antibodies via heteroligation between a high affinity HIV
epitope and a low affinity polyreactive site [27]. Having an autoimmune B cell repertoire that
escaped tolerance could also mean that there is a broader repertoire and wider spectrum of
specificities available to participate in immune responses, thus improving protective responses
against pathogens. The mature naïve B cell repertoire of SLE patients exhibits abnormalities in
the immunoglobulin (Ig) gene usage, with biases toward VH3, VH4-34, VK1 and VK4 gene
families [1, 3, 11, 12, 34]. How this altered repertoire affects the make-up of foreign antigen-
specific B cells could provide insights into the changes in B cell immunopoeisis in SLE patients.
Here, we investigated the B cell antibody responses in a cohort of SLE patients to character-
ize their post-GC foreign antigen-specific compartment in terms of antigen binding capacities
and level of autoreactivity. We generated monoclonal antibodies from acutely activated B cells,
plasmablasts, isolated from SLE patients and control subjects 7 days after influenza vaccination.
We report that influenza-positive antibodies from the SLE patients had higher avidity and neu-
tralization capacities against influenza than those from controls. Similar overall frequencies of
autoreactivity in the influenza-positive antibodies were seen in both cohorts, though differ-
ences in HEp-2 reactivity were noted. We describe distinct features in the gene repertoire of in-
fluenza-positive antibodies from SLE patients, and provide data suggesting that the enhanced
immune responses seen in SLE patients may be a consequence of cytokines that are abnormally
expressed in lupus. This study shows that at the level of individual plasmablasts, some SLE pa-
tients can generate a higher affinity response against foreign antigens than controls. This al-
tered response may reflect the underlying abnormalities due to lupus and investigating the
causes of the altered B cell responses could provide new avenues for delineating the cause
of lupus.
Materials and Methods
Patients and control subjects
The Oklahoma Medical Research Foundation and the University of Chicago institutional re-
view boards approved this study. Each volunteer provided his or her written informed consent.
Detailed information on the 10 SLE patients and 8 controls recruited for this study can be
found in S1 Table. Subjects that received vaccination in the 2006/07 vaccinating season were
S2, S6, S8, S10, C1, C3, C5, C6 and C8. Subjects that received vaccination in the 2007/08 season
were S1-8, S10 and C1-8. Subjects that received vaccination in the 2008/09 season were S1-6,
S8, S9, C1-4 and C6-8.
Monoclonal Antibodies
Antibodies were generated as previously described [35]. Briefly, peripheral blood was obtained
from each individual 7 days after influenza vaccination was administered. Lymphocytes were
purified and enriched for B cells with treatment of RosetteSep. Plasmablasts
(CD3-CD19+CD20lowCD27hi CD38hi) were single-sorted into 96-well plates, and RT-PCR, fol-
lowed by nested PCR, were used to amplify the variable heavy and light chain antibody genes
on a single-cell basis. The sequences were then cloned into IgG expression vectors and trans-
fected into HEK293 cells. HEK293 cells were obtained from American Type Culture Collection
(ATCC). Five days after transfection, antibodies were purified from the culture supernatant
using protein A agarose beads (Thermo Scientific) and subsequently concentrated.
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Virus and rHA ELISA
Influenza viruses were freshly grown in eggs, and purified as previously described [36]. 8 hem-
agglutination units (HAU) of virus were used for ELISA. Monoclonal antibodies were serially
diluted 1:3 starting at 30ug/ml and tested for reactivity against the three virus strains (H1N1,
H3N2 and B) in the corresponding vaccine and 1ug/ml of the respective rHA proteins (BEI Re-
sources, NIAID, NIH) by ELISA. Goat anti-human IgG peroxidase conjugate (Jackson Immu-
noResearch) was used to detect antibody binding. ELISA results for the virus strain each
antibody was most specific against, was used for analysis. KD values of antibody binding were
determined by Scatchard analysis using nonlinear regression (one site binding model) on
GraphPad Prism software.
Surface plasmon resonance
Kinetic interactions of the monoclonal antibodies (IgGs) with rHA protein were measured on
the ProteOn XPR36 (BioRad). Experiments were performed in HBS-EP running buffer. 20ug/
ml of goat anti-human IgG Fc fragment specific antibody (Jackson ImmunoResearch) in ace-
tate buffer pH5.5 was immobilized on a GLC chip at 30ul/min by amine coupling resulting in
around 3000RU. 5ug/ml of each antibody of interest was injected in running buffer at a flow
rate of 40ul/min for 60s for capture by the immobilized anti-IgG. For kinetic measurements,
rHA at five different concentrations ranging from 0.78125nM to 50nM in HBS-EP buffer was
injected at flow rate of 25ul/ml with 5 min association and 4 hour dissociation times. The sur-
face was regenerated by two injections of 0.85% phosphoric acid at 100ul/min for 18s each.
This removed antibody that was captured by the anti-IgG; hence leaving the immobilized anti-
IgG available for capturing another round of antibodies. For data analysis, double subtraction
(interspot (blank reference) and running buffer) was done. Affinities, or KD values, were calcu-
lated by aligning the data to 1:1 binding two-state model using ProteOn Manager v.3.1
(BioRad).
Hemagglutination inhibition assay
Influenza-positive monoclonal antibodies were tested for ability to inhibit hemagglutination of
the virus strain they bound. 8HAUs of virus in 25ul of PBS were incubated with 25ul of two-
fold diluted antibodies (60–0.234ug/ml) in duplicate for 30 minutes. 50ul of 1% of PBS-washed
Turkey RBCs (Lampire Biological Laboratories) was then added. The minimum effective con-
centration of each antibody was the lowest concentration of antibody that inhibited viral hem-
agglutination of RBCs.
Microneutralization assay
Influenza-positive monoclonal antibodies were tested for neutralization capacity against the
virus strain they bound as previously described [37]. 100TCID50 of virus in 50ul DMEM was
incubated with 50ul of three-fold diluted antibodies (60–0.027ug/ml) in triplicate at 37°C for 1
hour. This mixture was then added to PBS-washed MDCK cells for another hour. MDCK cells
were obtained from American Type Culture Collection (ATCC). Cells were then washed and
incubated in DMEM supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin,
0.5% BSA and 0.5 μg/ml TPCK-Trypsin for 70 hours. The minimum effective concentration of
each neutralizing antibody was the lowest concentration of antibody that inhibited viral infec-
tion as identified by the HA assay.
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Polyreactivity, HEp-2 ELISAs and immunofluorescence assay (IFA)
All antibodies were tested for polyreactivity and HEp-2 cell reactivity (INOVA Diagnostics) by
ELISA as previously described [1]. Antibodies were considered polyreactive when they bound
at least two of the following three antigens with an OD greater than 0.5: dsDNA, insulin and li-
popolysaccharide. For HEp-2 IFA, 50ug/ml of antibody was incubated on HEp-2 coated slides
(MBL Bion) for 30 min, washed with PBS and binding detected using FITC-conjugated anti-
human antibody by fluorescence microscopy. Positive and negative control sera used were in-
cluded in the kit. HEp-2 IFA reactivity was scored on a scale of 0–4, with 4 being the highest
level of reactivity, in a blinded manner by ten volunteers. The mode of the scores was used
for analysis.
Sequence analysis
Variable heavy and light chain antibody genes were analyzed for gene usage, mutations, CDR3
length and CDR3 isoelectric point (pI) using JOINSOLVER and the IMGT database.
Antibody Microarray
Antibodies were diluted in protein printing buffer to 250ug/ml and printed on SuperEpoxy
glass slides using the SpotBot 3 microarrayer (ArrayIt). Antibodies were spotted in triplicate on
each array. Printed slides were stored overnight at 4°C in the dark. Before each use, slides were
washed three times with PBS 0.05% Tween-20 and then treated with BlockIt blocking buffer
(ArrayIt) for 1 hr at room temperature. Slides were washed three times with protein microarray
wash buffer in between each step and all the reactions were done in protein microarray reaction
buffer (ArrayIt). To detect the antibodies spotted and normalize the signals, the slides were
then incubated for 1 hr with Cy3-conjugated goat anti-human IgG, Fc-fragment specific (Jack-
son). After washing, the slides were fitted with a 24 well hybridization cassette that allowed for
several different biotinylated rHAs at 20ug/ml each to be applied to a single array for 1 hr.
rHAs were biotinylated the previous day with EZ-Link Maleimide-PEG2-Biotin (Thermo-
Scientific). To detect bound rHA, slides were incubated with Alexa-Fluor 647-conjugated
Streptavidin (Invitrogen) for 1 hr. Signals were quantified by a GenePix 4000B microarray
scanner and analyzed with GenePix Pro 6.0 software (Molecular Devices).
Multiplex bead assay
Day 0 serum samples from 7 SLE patients and 7 control individuals were tested in duplicate for
32 cytokines using xMAP multiplex bead-based assay (Affymetrix) or ELISA (BLyS (R&D sys-
tems) and APRIL (eBiosciences)).
Statistical analysis
P values were calculated by comparing means using unpaired t-test or medians using Mann-
Whitney test with significance<0.05. All statistics were done with two-tailed analyses using
GraphPad Prism software. Spearman’s nonparametric correlation test with two-tailed analysis
was used to test the correlation between KD values measured by virus ELISA and SPR.
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Results
Generation of influenza-specific monoclonal antibodies from SLE
patients after influenza vaccination
To investigate the quality of antibody responses to foreign antigens in SLE patients, we express-
ed monoclonal antibodies (mAbs) from the cloned variable genes of single plasmablasts isolat-
ed from the 10 SLE patients and 8 healthy controls 7 days after they had received the trivalent
seasonal influenza vaccine (S1 Table). Plasmablasts are activated B cells found in the peripheral
blood only transiently after vaccination or infection and are typically antigen-specific [35, 36];
therefore, in contrast to serum antibodies or memory B cells, plasmablasts represent the B cells
specifically activated by ongoing immune responses only. While the percent of total B cells was
lower in the SLE patients compared to controls, the percent of plasmablasts
(CD3-CD19+CD20lowCD27hi CD38hi) out of total B cells was similar. In total, 446 mAbs were
generated, out of which 131 antibodies from SLE patients and 124 antibodies from controls
bound to influenza virus, as detected by enzyme-linked immunosorbent assay (ELISA) (S2
Table). Antibodies from each subject were tested against each of the three virus strains (H1N1,
H3N2 and B) present in the trivalent seasonal influenza vaccine. This allowed us to identify the
virus strain specificity of each antibody and the following results were obtained by testing each
antibody with its corresponding virus strain. Similar proportions of influenza-positive antibod-
ies from SLE patients and controls bound to each of the three different virus subtypes.
Influenza-positive antibodies from most SLE patients have higher
avidities
To evaluate the binding capacities of anti-influenza antibodies from the SLE patients and con-
trols, we tested all influenza-positive antibodies by ELISA to obtain half-maximal binding avid-
ities (KD) to whole influenza virions (S1 Fig). Influenza-positive antibodies from SLE patients
bound with significantly higher avidity (had lower KD values) than control antibodies (Fig 1A).
Furthermore, 6 out of 10 SLE patients (S1-6) had antibodies with median avidities above the
global median compared to only 2 out of 8 controls (C1, 2) (Fig 1B). A more robust analysis of
the affinities of 80 antibodies (53 from SLE patients and 27 from controls) using surface plas-
mon resonance (SPR), showed strong correlation with the virus ELISA KD values across a
range of affinities, verifying these results (Fig 1C, S3 Table). We conclude that the influenza-
positive antibodies from some of the SLE patients have higher binding avidities to influenza
virus than those from controls. This suggests that these high avidity antibodies from SLE pa-
tients would display improved protective capacities against influenza.
Improved HAI and neutralization capacities observed for antibodies from
SLE patients
Protective antibodies against influenza neutralize virions and prevent infection of host cells
most often by binding and inhibiting the function of hemagglutinin (HA) and neuraminidase
(NA) viral proteins [38]. The two most common in vitromethods for detecting such antibod-
ies, the HAI assay and the microneutralization (MN) assay, were used to test the influenza-pos-
itive antibodies. Increased avidities correlate well with increased neutralization capacities (S1
Fig), thus antibodies from SLE patients had significantly better (lower) minimum effective con-
centrations for both HAI (Fig 1D) and neutralization (Fig 1E). Though not significant, there
was also a tendency for a greater proportion of the SLE antibodies to be microneutralizing (p
value = 0.07). We conclude from these experiments that functional capacities of individual in-
fluenza-positive antibodies are higher when from SLE patients.
Monoclonal Antibody Responses against Influenza in Lupus Patients
PLOS ONE | DOI:10.1371/journal.pone.0125618 May 7, 2015 6 / 21
Fig 1. Higher avidities and neutralization capacities observed for monoclonal antibodies from SLE patients. (A) Monoclonal antibodies generated
from plasmablasts isolated from subjects were tested for virus binding by ELISA. Binding avidities (KD) were estimated by Scatchard plot analyses of ELISA
data. KD values of pooled antibodies are shown. Medians were compared using Mann-Whitney test. (B) The distribution of KD values is shown by subject.
Each bar graph represents the median of the avidities of antibodies (represented by symbol) for each subject. The red dotted line represents the global
median avidity of all SLE and control influenza-positive antibodies. (C) Avidities of 53 influenza-positive antibodies from SLE patients and 27 from controls
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The above results suggest that in the context of lupus, improved antibody responses can be
generated against foreign antigens. However, with some SLE patients generating a greater pro-
portion of particularly higher affinity antibodies (S1-6) and others generating a greater propor-
tion of lower affinity antibodies (S7-10), it appeared that there were both high and low
responders in the SLE cohort. SLE is a complex, heterogeneous disease and the patients may
have different degrees of immune system abnormalities that may in turn influence their B cell
antibody responses to different extents. It has also been reported that immunosuppressive
treatment can affect the serological responses of patients to vaccination [17, 23] but we could
not find a correlation between the median avidity of the anti-influenza antibody responses and
immunosuppressive treatments of the SLE patients (S1 Table). We then examined other factors
such as autoreactivity levels and gene usage that could potentially distinguish between the high
and low avidity responders as well as provide insights into the foreign antigen-specific com-
partment of SLE patients.
Similar overall levels of autoreactivity seen in influenza-positive
antibodies from SLE and control subjects
One of the hallmark characteristics of SLE is the breakdown of primary B cell tolerance that
leads to high numbers of polyreactive and self-reactive mature naïve B cells [2]. In addition,
secondary tolerance is also disrupted in lupus, possibly leading to higher autoreactivity in the
post-GC compartment. The observations that broadly neutralizing anti-HIV are polyreactive
and self-reactive suggest that autoreactivity may be an advantageous characteristic for in-
creased affinity [26, 29, 39]. However, SLE patients with high pre-existing titers of autoantibod-
ies have lower serological responses to influenza vaccination [17], indicating instead that
increased autoreactivity may be detrimental to a foreign-antigen response. Hence, we wanted
to learn if the antibodies from SLE patients are more autoreactive than those from controls and
whether the level of autoreactivity could differentiate between the high and low influenza vac-
cine responders. At the same time, analyses of the autoreactivity of the plasmablasts would
allow us to evaluate the efficiency of secondary tolerance mechanisms operating in SLE patients
during immune responses against foreign antigens.
To determine the level of polyreactivity in the plasmablast population of SLE patients, we
tested all antibodies generated for reactivity against double-stranded DNA (dsDNA), insulin,
and lipopolysaccharide (LPS) by ELISA. The frequency of polyreactive antibodies was similar
for influenza-positive antibodies from SLE patients and controls (Fig 2A). There was also no
difference in the frequency of polyreactivity for the influenza-negative antibodies (75 from SLE
patients and 116 from controls) (S2A Fig). To determine if influenza-positive antibodies from
SLE patients were self-reactive, we tested the antibodies for reactivity against human HEp-2
cells by ELISA and immunofluorescence assay (IFA). In each assay, although the frequency of
influenza-positive antibodies with HEp-2 reactivity tended to be higher for SLE patients than
for controls, it was not statistically different (Fig 2B and 2C). Consistent with this, when we
combined the results of HEp-2 ELISA and IFA, we found that the percentage of total HEp-2 re-
activity was higher for influenza-positive antibodies from SLE patients, although again not sig-
nificantly (S2B Fig). Overall, the frequency of polyreactive and/or HEp-2-reactive influenza-
were measured by SPR. Correlation between approximated KD values from virus ELISA data and KD values measured by SPR is shown. Black symbols are
antibodies from SLE patients while blue are those from controls. Correlation was determined by Spearman’s correlation test. (D-E) Influenza-positive
antibodies were serially diluted and tested in the standard HAI assay (D) and microneutralization (E) for functional capability. Medians were compared using
Mann-Whitney test. (D) Minimum antibody concentration effective at inhibiting hemagglutination is plotted for each HAI-positive antibody. (E) Same as (D),
except for microneutralization. Results are representative of at least three independent replicates.
doi:10.1371/journal.pone.0125618.g001
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Fig 2. Poly- and self-reactivity of influenza-positive antibodies. Antibodies were tested for polyreactivity against dsDNA, LPS and insulin by ELISA and
for HEp-2 reactivity by ELISA and IFA. (A) Pie charts represent the frequency of polyreactive and non-polyreactive influenza-positive antibodies for each
individual. Numbers in the center indicate number of influenza-positive antibodies for each individual. Dot plot (right) summarizes the percent of polyreactive
antibodies from the pie charts; each symbol represents an individual. (B) Similar to (A), except for HEp-2 ELISA reactivity. (C) Distribution of the HEp-2 IFA
scores for each individual is shown and the dot plot summarizes the percent of antibodies with a score of 2 and above for each individual. (D) Distribution of
antibodies with HEp-2- only, poly- only and both reactivities is shown for pooled influenza-positive antibodies in the pie charts. Values in pie chart segments
are percentages. Statistical significance of the difference between the two cohorts was determined by the Chi-squared test (*p<0.05; **p<0.001;
***p<0.0001). Dot plots show the percent of each type of reactivity for each individual. (E) Average HEp-2 IFA score of all influenza-positive antibodies for
Monoclonal Antibody Responses against Influenza in Lupus Patients
PLOS ONE | DOI:10.1371/journal.pone.0125618 May 7, 2015 9 / 21
positive antibodies was not significantly different between SLE patients and controls (Fig 2D).
The frequency of self-reactive antibodies in the influenza-negative population was higher for
SLE patients than controls (S2C and S2D Figs). This is consistent with past reports of increased
CD27hi B cells that reflect SLE disease activity [12, 13]. These data indicate that analogous to
IgG memory B cells [5], the overall frequencies of polyreactive and HEp-2 reactive antibodies
in the foreign antigen specific compartment of SLE patients are similar to that of controls.
Although not significant, the tendency for the percentage of HEp-2 reactivity by ELISA and
IFA to be higher in SLE patients is nonetheless intriguing. To understand this better, we segre-
gated the antibodies by their binding properties: HEp-2 ELISA reactive only, polyreactive only,
and both HEp-2 ELISA reactive and polyreactive. While most self-reactive influenza-positive
antibodies from controls were also polyreactive, the self-reactive influenza-positive antibodies
from SLE patients tended to be only specific for HEp-2 antigens. This was observed both when
antibodies were pooled and when segregated by individual (Fig 2D). This tendency was also ob-
served for influenza-negative antibodies (S2E Fig). This indicates that the HEp-2 reactivity dis-
played by majority of the antibodies from controls may be a result of their inherent
polyreactivity, thus leading to percentages of HEp-2 reactivity in controls that were skewed
higher and not significantly different from that of SLE patients. In support of this, we found
that the average HEp-2 IFA score of influenza-positive antibodies for each subject was signifi-
cantly higher in the SLE patients than controls and there were more anti-nuclear antibodies in
the SLE antibody set (Fig 2E, S2F and S2G Figs). These subtle differences between the self-reac-
tive antibodies from SLE patients and those from controls suggest that while self-antigen spe-
cific B cells in SLE patients can survive secondary tolerance in the GC, selection against
polyreactivity or other autoreactive epitopes in secondary lymphoid organs may be intact. To
directly test if polyreactivity can be removed during foreign-antigen immune responses in SLE
patients, we reverted four influenza-positive antibodies from SLE patients back to their pre-
dicted germline configuration and assayed their binding to polyreactive antigens. We found
that two of the four antibodies became dsDNA reactive when expressed as unmutated, germ-
line precursors, indicating that dsDNA reactivity of those two antibodies had been removed by
somatic hypermutation (S2H Fig). Although strong conclusions cannot be drawn from analy-
ses of only four antibodies, these data in combination with the increased HEp-2 reactivity sug-
gest that autoreactive B cells in SLE patients may contribute to immune responses to
foreign antigens.
Higher percentage of autoreactive influenza-positive antibodies in most
low responders
Although we could identify 9 HEp-2-reactive neutralizing antibodies (out of 51) from SLE pa-
tients, on the whole, autoreactivity did not correlate with increased influenza binding or neu-
tralization capacity. Instead, SLE patients who had high avidity anti-influenza antibody
responses (S2, S3 and S4) had low percentages of autoreactivity in their influenza-specific com-
partment whereas low responding patients (S8, S9 and S10) had high percentages of autoreac-
tivity in their influenza-specific compartment (Figs 1 and 2). This observation is comparable to
a past serological study that reported patients with high antinuclear antibody titers were low re-
sponders [17]. Our findings of the two SLE antibodies that displayed dsDNA reactivity when
reverted to germline provide support that lower affinity binding to antigen is associated with
each individual is plotted. Medians were compared by Mann-Whitney test in A-C, D (dot plot), E; and data are representative of at least three
independent replicates.
doi:10.1371/journal.pone.0125618.g002
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autoreactivity. Within the controls, a similar relationship between high avidity response and
autoreactivity levels was seen. Controls C1 and C2 who had high avidity anti-influenza anti-
body responses, had lower percentages of autoreactivity compared to the other controls. On
the other hand, SLE patients S5 and S6 have high avidity anti-influenza antibody responses de-
spite having high levels of autoreactivity. Hence, within our cohort with respect to influenza, it
is inconclusive if autoreactivity is advantageous to the anti-influenza response. In the field of
HIV, polyreactivity is proposed to improve the affinity of anti-HIV antibodies by giving them
an advantage in binding low density epitopes on HIV through heteroligation. Unlike homoty-
pic bivalent binding, heteroligation involves one antibody-binding site binding to the HIV en-
velope protein and the other cross-reacting to a low affinity site on another structure [26, 27].
On the contrary, the density of influenza HA and NA would allow for high avidity epitope-spe-
cific interactions by both antibody-binding sites without a selective advantage for autoreactive
B cells. Autoreactivity could therefore be a property that is acquired through somatic mutations
without a subsequent selective advantage against influenza.
Biases in gene repertoire of influenza-specific plasmablasts from SLE
patients
Next, we investigated the hypothesis that autoimmune B cell repertoires may have altered spec-
ificities that are otherwise removed from healthy individuals by intact primary tolerance mech-
anisms. Differences in the gene repertoire of influenza-specific plasmablasts could also reflect
differences in B cell selection in the GCs between SLE patients and controls. We analyzed the
variable heavy (VH) chain and kappa (VK) chain genes of influenza-specific antibodies from
both cohorts to determine if there were differences in the plasmablast repertoires of SLE pa-
tients and controls. Although a greater number of subjects in the SLE cohort had clonally relat-
ed sequences, overall, the proportion of clonally related sequences was similar between SLE
patients and controls (Fig 3A). When we analyzed only unique clones, we observed similar re-
sults for the differences in influenza binding avidity between SLE patients and controls as in
Fig 1. Since the clones did not skew the influenza binding data and each monoclonal antibody
herein represents an individual plasmablast that was activated during the immune response
against influenza, each antibody has equal weight in the analysis.
The number of somatic hypermutations in the VH and VK genes of influenza-positive anti-
bodies from SLE patients and controls was similar when compared both by antibody and when
averaged by subject (Fig 3B). This indicates that plasmablasts from both groups had similar lev-
els of immune experience. Previous or repeated exposures to natural influenza infections or
vaccinations greatly influence the immune response to a current influenza vaccination and the
frequency of accumulated somatic mutations correlates with cross-reactivity to past influenza
strains and thus with immune history[37]. We could not directly address the role of immune
experience in the high and low responders within the SLE group and between the SLE patients
and controls, as it is difficult to fully account for the lifetime history of influenza exposure of
each subject. The similar levels of somatic mutations provide some evidence that immune ex-
perience to influenza is similar in the two groups. The average number of non-synonmous mu-
tations in the CDR1 and 2, and framework regions was also not different for influenza-positive
antibodies from SLE patients and controls.
In terms of the gene usage of influenza-positive antibody sequences, we found that SLE pa-
tients had a higher proportion of antibodies with long complementarity-determining region 3
(CDR3) segments ( 20 amino acids) in the VH chains (Fig 3C), as well as an increased usage
of the joining (JH6) gene segment (Fig 3D). These two differences were not seen in the influen-
za-negative plasmablasts of SLE patients compared to that of controls. The predicted VH
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Fig 3. Heavy and light chain gene features of influenza-specific antibodies from SLE patients and controls. (A) Pie charts show the proportion of
clonally related sequences in the influenza-positive antibodies from SLE patients and controls. (B) Number of somatic mutations in VH and VK chain gene
sequences of influenza-positive antibodies is plotted. For each graph, in the left panel, each symbol represents an individual antibody, while in the right panel;
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CDR3 isoelectric point (pI) was also significantly reduced for SLE influenza-specific antibodies
(Fig 3E). During normal B cell development, long CDR3 segments and JH6 gene segments are
counter-selected and their presence in the naïve B cell repertoire has been correlated with auto-
immune repertoires [1, 40–43]. How these features of the antibody genes may influence the
binding capacities of antibodies has yet to be investigated. Nevertheless, these differences in
repertoires support a model in which the known break in primary B cell tolerance of SLE pa-
tients [1–3] leads to the production of a wide spectrum of autoreactive naïve B cells that are
only partially controlled during foreign-antigen specific immune responses. Alternatively, it
suggests that B cell selection in the GCs of SLE patients is altered, leading to unique repertoire
properties in the post-GC compartment.
Similar specificities seen in SLE and control antibodies
We then examined whether antibodies from SLE patients and controls differed in the targeting
of influenza antigens. We found that similar proportions of antibodies from SLE patients and
controls bound to recombinant HA (rHA) and to the conserved HA stalk versus the more
strain-specific HA-head epitopes. Further, H1N1 and H3N2 rHA-specific antibodies from SLE
patients and controls had similar levels of cross reactivity to multiple influenza strains when
tested against a panel of rHA from past and diverse influenza strains using an antibody micro-
array (S3 Fig and S4 Table). These results suggest that the antibodies from SLE patients did not
have differences in epitope targeting or breadth of variant influenza strains recognized and
thus differential targeting of influenza antigens may not likely account for the improved influ-
enza binding by SLE patient antibodies.
Role of cytokines in high avidity antibody responses
Another characteristic typical of SLE is the abnormal levels of various cytokines. Several cyto-
kines are known to be dysregulated in SLE patients [44–47] and we reasoned that this could be
a factor in determining the quality of foreign-antigen immune responses as germinal center re-
actions and B cell activation are greatly influenced by cytokines. Cytokines associated with SLE
disease activity, such IL-2 and IFN- γ, profoundly affect T helper cell function and germinal
center reactions, which then impacts antibody production by B cells [24, 48, 49]. To determine
if serum cytokine levels could account for the high versus low avidity responses, we measured
the pre-vaccination (day 0) levels of a panel of 32 cytokines by multiplex cytokine bead assay
or ELISA. High levels of proinflammatory cytokines such as IL-1β, IFN-γ, IL-6, TNFα, and
TNFRII; T cell cytokines such as IL-4, IL-12p70 and IL-2, as well as chemokines were seen in
SLE patients (S1-4) who went on to produce a stronger anti-influenza response (Fig 4A). Inter-
estingly, this same cytokine profile was observed for C1, the control individual with a large pro-
portion of antibodies with high avidity (Fig 4A). The n value of subjects studied herein was not
large enough to accurately access the correlation between the avidity of the anti-influenza re-
sponse and the level of specific cytokines. In conclusion, these data suggest that pre-vaccination
levels of key cytokines and chemokines that support GC reactions may influence the produc-
tion of a high affinity response. Future experiments with a larger dataset would be needed to
test this proposed hypothesis.
each symbol is the average number of mutations of all the antibodies for each individual. (C) Proportion of influenza-positive antibodies with different variable
heavy (VH) CDR3 lengths (number of amino acids). (D) Proportion of pooled antibodies with different joining region JH, VH, VK and JK gene identities. (E)
Isoelectric points of VH chain CDR3 gene segments of influenza-positive antibodies from SLE patients and controls. The left panel shows each symbol
representing an individual antibody, while in the right, each symbol is the average of all the antibodies for each individual. Means were compared in B and E
using unpaired t-test. Chi-squared test was used to compare the frequency of the individual categories between SLE and controls (* p < 0.05) in C and D.
doi:10.1371/journal.pone.0125618.g003
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Discussion
Influenza vaccination is routine for SLE patients and there have been many serological studies
published that provide assessments of the antibody responses SLE patients make to the vaccine
relative to healthy controls. Some studies showed that SLE patients have lower seroconversion
rates while others reported no significant differences in serum antibody titers between vacci-
nated SLE patients and healthy individuals [14, 17, 20–22, 50]. The variability in the results of
these studies possibly reflects diversity in the demographics of patient cohorts, disease hetero-
geneity and the varying degrees of patients’ lymphopenia. These issues, the lymphopenia of pa-
tients in particular, make serological data regarding the effects of lupus on the quality of B cell
responses inconclusive, as it is difficult to distinguish between quantity of specific antibodies
and quality of individual antibodies. Here, we specifically examined the quality of individual B
cells activated in SLE patients by generating influenza-specific monoclonal antibodies from
plasmablasts. We showed that higher binding avidities and neutralization capacities against in-
fluenza were observed for antibodies from SLE patients; with 6 of the 10 patients being the
main contributors of high affinity antibodies.
The diversity seen in the responses of the SLE patients prevent us from making definite con-
clusions about the anti-influenza response generated in the context of lupus. Nonetheless, the
generation of high affinity and more protective antibodies against influenza in SLE patients
S1-S6 is interesting and it brings to mind the notion of autoimmunity as a selective advantage.
Despite the ability of SLE patients to generate higher affinity antibodies, as suggested by our
study, it has been reported that SLE patients have greater susceptibility to infectious diseases
[51, 52]. This susceptibility is likely due, in parts, to reduced vitality resulting from autoim-
mune comorbidities, immunosuppressive therapy [17, 51], and disease-associated immune ab-
normalities such as leukopenia [12, 23, 53] that would impact the overall quantity of the
immune response. Hence, the above contradiction suggests that an autoimmune tendency,
without morbidity, could in fact mean improved protection against infections. The next impli-
cation of this interpretation leads us to a long-standing theory that autoimmunity developed as
an unintended consequence of the host evolving to improve immune responses against patho-
gens. This hypothesis has been considered in the context of some infections. For example, a
polymorphism of inhibitory receptor FcγRIIb protects individuals against malaria but increases
susceptibility to systemic lupus erythematosus (SLE) [54–56] and the occurrence of HIV infec-
tions in SLE patients is disproportionately low [31–33].
There are several hypotheses that could explain the association between autoimmunity and
improved immune responses and provide insights into the underlying abnormalities of auto-
immune diseases. One hypothesis is that individuals who in general produce higher affinity an-
tibodies have an increased risk for autoimmunity. In the event that tolerance for self is also
disrupted, as suggested by past studies [2, 3, 57], then high affinity, pathological self-reactive
antibodies could be produced at some frequency. These high affinity autoantibodies would be
more damaging, causing a cascade effect where linked self-antigens are also targeted, leading to
Fig 4. Distinct serum cytokine profiles seen in subjects with high avidity antibodies andmodels discussing the production of high affinity
antibodies in context of autoimmunity. (A) The levels of various cytokines in the serum of subjects, measured by multiplex bead assay, are shown on a
graded color scale. Cytokines are grouped according to their major roles in immune responses and subjects are ranked by the median avidity of each subject
as shown in Fig 1D. Serum cytokine levels were normalized by the minimum (blue) and maximum (red) values within each dataset. (B) The affinity-risk model
postulates that individuals who have the propensity to make high affinity responses will have higher risk for autoimmunity, especially if primary B cell
tolerance mechanisms are also disrupted and the naïve B cell population is more self-reactive than normal. Thicker red arrows indicate greater probability of
the event. (C) The autoreactivity-risk model proposes that anergy (or other factors) may be contribute to the increased activation threshold of self-reactive B
cells in SLE patients so that only B cells with high enough affinity for the antigen are activated, thus skewing the response towards a higher affinity B
cell response.
doi:10.1371/journal.pone.0125618.g004
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epitope spreading and eventual systemic autoimmunity (Fig 4B). In this case, natural selection
for high affinity antibody responses, that would be beneficial against pathogens, could pose an
autoimmunity risk.
Increased JH6 gene usage and long VH CDR3 segments, often seen in autoimmune reper-
toires, were enriched in the influenza-positive antibodies from SLE patients. Although we were
not able to determine how these features allowed for enhanced influenza binding, it has been
demonstrated by other studies that long CDR3 loops in anti-HIV and anti-influenza antibodies
can extend into the receptor binding pockets of the antigen and contribute to the neutralization
potency of the antibodies [58–61]. The observations on the repertoire differences support the
hypothesis that due to impaired primary tolerance, the B cell repertoire available for immune
responses against pathogens in SLE patients is less restricted. Consistent with this, another
study showed that the IgG memory repertoire of SLE patients had altered VK2 gene family and
VK3-20 usage [5]. It would be interesting to investigate if biases in the repertoire are seen in
the antibody responses of SLE patients, relative to controls, for other pathogens.
Cytokines play important roles in immune system regulation and are an active area of inves-
tigation in lupus research. Several genetic polymorphisms associated with SLE affect cytokine
signaling and alter cytokine profiles. For example, the risk allele of PTPN22 affects serum levels
of interferon-α and TNF-α while the STAT4 risk allele affects serum levels of interferon-α
[46]. We found distinct cytokine profiles (increased levels of IL-1β, IFN-γ, IL-6, TNFα,
TNFRII, IL-4, IL-12p70 and IL-2) for subjects with higher avidity antibody responses (high re-
sponders) compared to those who had a lower avidity antibody response (low responders).
These cytokines influence various immune cells, including B cells directly and indirectly
through T cells and dendritic cells and therefore, would impact germinal center reactions dur-
ing foreign-antigen responses. How the specific cytokines can contribute to the production of
high affinity antibodies needs further investigation. Examining the cytokine profiles of a large
cohort of healthy individuals in relation to their vaccination responses could provide insights
for improving vaccine efficacy in low responders.
Yet another factor, not investigated herein, is the role of anergy. Human autoreactive naïve
B cells have been reported to be anergic and intense stimulation is required for them to fully re-
spond [40, 62]. It is possible that the high responders may have a high frequency of autoreac-
tive lymphocytes that would be chronically stimulated, leading to anergy and reduced
activation potential. Reduced activation potential would mean that the B cells require greater
levels of stimulation to be activated. Hence, only the highest affinity B cells are activated and
enter an immune response, resulting in the production of higher affinity antibodies (Fig 4C).
This possibility is supported by our observation that reverting two SLE antibodies to germline
configurations restored their DNA reactivity.
Genetic polymorphisms that are associated with SLE mediate risk of disease by altering im-
mune regulation pathways, some of which overlap with pathways that are involved in immuni-
ty against pathogens. In fact, several studies have found that polymorphisms in viral RNA
sensors such as Toll-like receptor 7 and MDA-5, also result in autoimmunity [63–66]. The link
between viral immunity and autoimmune diseases provides insights into the evolutionary de-
velopment of autoimmunity and also presents opportunities to study autoimmunity from a dif-
ferent perspective. The mechanistic basis of lupus in diverse human populations is at best
poorly understood. Studying the generation of high avidity antibody responses in the context
of dysregulated immunity could not only provide insights into mechanisms of immune re-
sponses against foreign antigens but also provide a new avenue for investigating the mecha-
nisms of systemic autoimmune diseases.
In conclusion, we found that high affinity anti-influenza antibodies characterize the plasma-
blast response of SLE patients after influenza vaccination. It will be important to determine if
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similar observations are seen with other infections or vaccines, and in untreated SLE patients
or unaffected family members.
Supporting Information
S1 Fig. Avidities and minimum effective concentrations of anti-influenza antibodies. Sum-
mary of the avidities and minimum effective concentrations in HAI and MN assay is shown for
all influenza-positive antibodies (131 antibodies from SLE patients and 124 antibodies from
controls). Each bar represents an antibody and grouping of antibodies is by subjects. Avidities
were estimated by Scatchard plot analyses of ELISA data. Red lines indicate the global medians
of all antibodies positive for the assay. (S-SLE; C-Control).
(EPS)
S2 Fig. Poly- and self-reactivity of human monoclonal antibodies. (A-D, except B) Reactivity
of influenza-negative antibodies. (A) Dot plot summarizes the percent of polyreactive antibod-
ies in the influenza-negative antibody set from SLE patients and controls; each symbol repre-
sents an individual. (B) Dot plot summarizes the percent of HEp-2 reactive antibodies either
by HEp-2 ELISA or IFA in the influenza-positive population of each individual. (C) Similar to
(A), except for HEp-2 ELISA reactivity. (D) Dot plot summarizes the percent of influenza-neg-
ative antibodies with a HEp-2 IFA score of 2 and above for each individual. (E) Dot plots show
the percent of each type of reactivity (poly- only, HEp-2 only or both) for the influenza-nega-
tive antibodies for each individual. Medians were compared by Mann-Whitney test in A-E and
data are representative of at least three independent replicates. (FE) Distribution of the type of
HEp-2 staining is shown for both influenza-positive and negative antibodies from SLE patients
and controls. Representative images for each type of staining are shown within the legend. P
values were determined by comparing SLE and control group using chi-squared test (p<0.05;
p<0.001; p<0.0001). (G) Slide images of 18 SLE and 4 control antibodies with a score of 4
are shown. (H) Graphs show the reactivity of 4 influenza-positive antibodies from SLE patients
(mutated and reverted versions) to dsDNA by ELISA. Each antibody was reverted to germline,
synthesized and tested against dsDNA alongside its original, mutated version. Horizontal lines
show the cut-off OD405 for positive reactivity. Data shown is representative of three
independent replicates.
(EPS)
S3 Fig. Cross-reactivity of rHA-positive antibodies. H1N1 and H3N2 recombinant HA
(rHA)-positive antibodies were printed on a slide, each in triplicate, and incubated with various
rHAs from previous and divergent influenza vaccine strains in an antibody microarray set-up.
Signals were normalized to an internal control for each strain to obtain the relative level of
binding of each antibody for the rHA. The relative level of binding of each antibody is shown
on a color scale, with 100% (red) being the highest. An antibody was called cross-reactive if it
had detectable binding to more one strain. The strains written in bold were in the vaccines re-
ceived by subjects in this study. Results shown here are representative of three
independent experiments.
(EPS)
S1 Table. Information on the 10 SLE patients and 8 controls from whom plasmablasts were
isolated 7 days after influenza vaccination and antibodies were generated.
(PDF)
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S2 Table. Repertoire and reactivity of all antibodies expressed from SLE patients (206 anti-
bodies) and controls (240 antibodies).
(PDF)
S3 Table. Binding kinetics data of 80 antibodies measured by surface plasmon resonance.
(PDF)
S4 Table. Array data on cross-reactivity of rHA-specific antibodies.
(PDF)
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